Obecabtagene Autoleucel
Phase 2Cell therapy
This medication is a type of immunotherapy made from a patient's own immune cells that has been specially engineered to recognize and attack acute lymphoblastic leukemia cancer cells. It is used to treat adults with this type of blood cancer when it has returned or stopped responding to other treatments.[1] Obecabtagene Autoleucel is currently being investigated across 6 indications[3], with its most advanced program in Phase 2.[1]
Obecabtagene Autoleucel is one of 192 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.
6
Indications
5
Total Trials
5
Active Trials
191
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Obecabtagene Autoleucel
AAutolus Limited
Phase 2
Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Flomax
SanofiPreclinical
Novantrone
PfizerPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Lunesta
Akero TherapeuticsPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Obecabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 2[1]
- Company
- AAutolus Limited